GNH USA

Europe — EMA

Miglustat Dipharma

GNH USA supplies Miglustat Dipharma (Miglustat), a glucosylceramide synthase inhibitor for Niemann-Pick type C and Gaucher type 1. Request a quote for supply.

Miglustat

Request sourcing

1
Pack/s

What is Miglustat?

Miglustat, the active ingredient in Miglustat Dipharma, is a glucosylceramide synthase inhibitor presented as an oral formulation for oral use. It is employed in the management of lysosomal storage disorders such as Niemann‑Pick disease type C and Gaucher disease type 1, where it reduces glycosphingolipid synthesis. The drug acts systemically after absorption, offering a convenient oral alternative to enzyme replacement therapies.

GNH USA supplies Miglustat Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide and research institutions.

What is Miglustat used for?

Miglustat is used as substrate reduction therapy targeting glycosphingolipid accumulation in lysosomal storage disorders. - Niemann-Pick disease type C: slows neurological decline and improves survival. - Gaucher disease type 1: reduces spleen and liver size and improves blood counts. - Substrate reduction therapy: provides an oral option to lower glycosphingolipid synthesis in applicable lysosomal storage disorders.

What are the side effects of Miglustat?

Miglustat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea - Nausea - Abdominal pain - Weight loss

Serious or Rare Side Effects: - Pancreatitis - Severe hypersensitivity reactions - Elevated liver enzymes

What precautions apply to Miglustat?

When prescribing Miglustat, clinicians should consider several safety measures to minimize risk. - Monitor gastrointestinal tolerance: assess for persistent diarrhea or nausea. - Check liver function: perform baseline and periodic liver enzyme tests. - Evaluate metabolic status: observe blood glucose and weight changes. - Assess mental health: watch for signs of depression or mood alterations. - Store at ambient temperature: keep in original packaging, protect from moisture.

What does Miglustat interact with?

Miglustat can interact with other medicines, affecting its concentration or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase miglustat exposure and toxicity. - High-dose oral antidiabetics: combined use can heighten risk of hypoglycemia. - Concurrent substrate reduction agents: additive effects may raise adverse event risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: may lower miglustat levels and reduce efficacy. - Antacids containing magnesium or aluminum: can impair miglustat absorption.

Frequently asked questions

What is Miglustat Dipharma used for?+
Miglustat Dipharma is indicated for the treatment of certain lysosomal storage disorders, specifically Niemann‑Pick disease type C and Gaucher disease type 1. In these conditions it works as substrate reduction therapy to lower the accumulation of glycosphingolipids that cause organ and neurological damage.
How does Miglustat work?+
Miglustat inhibits glucosylceramide synthase, the enzyme that initiates glycosphingolipid synthesis. By blocking this step, the drug reduces the production of glucosylceramide and downstream complex lipids, decreasing their storage in lysosomes and helping to restore normal cellular function.
What is the usual dose of Miglustat Dipharma?+
The dosage of Miglustat Dipharma is individualized and must be determined by a qualified prescriber based on the patient’s condition, age, weight, renal function and other clinical factors. No fixed dosing regimen is provided here.
Is Miglustat safe in pregnancy or breastfeeding?+
Safety data for Miglustat in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.
How do I order Miglustat Dipharma from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Miglustat compare with the main alternative therapy?+
The primary alternative for many lysosomal storage disorders is enzyme replacement therapy (e.g., imiglucerase for Gaucher disease). Miglustat offers an oral, small‑molecule approach that reduces substrate synthesis, whereas enzyme replacement supplies the missing enzyme intravenously. Choice depends on disease severity, patient preference, and clinical response.
What are the storage and handling requirements for Miglustat Dipharma?+
Miglustat Dipharma should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.
How is Miglustat administered?+
Miglustat is taken orally, usually with a glass of water. It may be recommended to take the dose with food to lessen gastrointestinal discomfort, but the exact administration instructions should follow the prescribing information provided by the healthcare professional.
What are the most serious risks associated with Miglustat?+
Serious adverse events to monitor include pancreatitis, severe hypersensitivity reactions such as rash or anaphylaxis, and significant elevations in liver enzymes indicating hepatic injury. Prompt medical evaluation is required if any of these symptoms arise.
Who should not use Miglustat Dipharma?+
Miglustat should be avoided in patients with known hypersensitivity to the drug or its excipients, and in those with severe hepatic impairment where the risk may outweigh benefit. Clinicians should also exercise caution in patients with pre‑existing pancreatic disease or uncontrolled metabolic conditions.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Miglustat
Route
Oral Use
Manufacturer
Dipharma Arzneimittel Gmbh
Origin
EU

Related products

Miglustat 100 mg/1

Miglustat 100 mg/1

Miglustat · 100 mg

Miglustat
CAPSULE
CoTherix, Inc.
USA
Zavesca 100 mg

Zavesca 100 mg

Miglustat · 100 MG

Zavesca
CAPSULE
JANSSEN INC
CANADA
Sandoz Miglustat 100 mg

Sandoz Miglustat 100 mg

Miglustat · 100 MG

Sandoz Miglustat
CAPSULE
SANDOZ CANADA INCORPORATED
CANADA
Miglustat Accord

Miglustat Accord

Miglustat

Accord Healthcare Limited
EU